Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410927 · ClinicalTrials.gov registry record · Phase 1
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03410927 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 19 participants.
The verdict
NCT03410927, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard therapy or for which no standard therapy exists, particularly urothelial cancer, biliary tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.
Interventions
- DRUG TAS0728
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03410927
The ClinicalTrials.gov registry entry for NCT03410927 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS0728 is the first listed.
NCT03410927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03410927 about?
NCT03410927 is a clinical study titled "A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities". This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with HER2 or HER3 overexpress...
What is the current status of trial NCT03410927?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-04-06. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT03410927?
The interventions under investigation include: TAS0728 (DRUG).
Who is sponsoring clinical trial NCT03410927?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.